Results 141 to 150 of about 10,133 (174)
Some of the next articles are maybe not open access.
Central diabetes insipidus in children.
Acta Endocrinologica, 1987Abstract. The antidiuretic effect and pharmacokinetics of 10 to 20 μg of intranasal (IN) and 200 to 400 μg of oral (po) 1-deamino-8-D-arginine vasopressin (DDAVP) were studied in 10 paediatric diabetes insipidus patients. A significant increase in urine osmolality was obtained with all doses, maximum within 2 h and still present at 8 h.
Anne Fjellestad-Paulsen +3 more
openaire +1 more source
DDAVP in the Treatment of Central Diabetes Insipidus
New England Journal of Medicine, 1976DDAVP, 1-desamino-8-d-arginine-vasopressin, is a synthetic analogue of vasopressin with increased antidiuretic activity and decreased pressor activity. Whereas the antidiuretic-to-pressor ratio of arginine vasopressin is 1, the antidiuretic-to-pressor ratio of DDAVP is 4000.
openaire +2 more sources
Genetics and diagnosis of central diabetes insipidus
Annales d'Endocrinologie, 2012Most of the central diabetes insipidus cases seen in general practice are acquired but the rare cases of hereditary autosomal dominant or recessive neurohypophyseal diabetes insipidus have provided further cellular understanding of the mechanisms responsible for pre-hormone folding, maturation and release.
openaire +2 more sources
Central diabetes insipidus: beware of Langerhans cell histiocytosis!
The Netherlands journal of medicine, 2018Langerhans cell histiocytosis (LCH) is a rare disorder, characterised by a monoclonal proliferation of aberrant histiocytes that accumulate in and infiltrate into different organs. When the hypothalamic-pituitary axis is involved, central diabetes insipidus (CDI) can be its first manifestation.
Brys, A D H +4 more
openaire +3 more sources
Acquired forms of central diabetes insipidus: Mechanisms of disease
Best Practice and Research in Clinical Endocrinology and Metabolism, 2020Joseph G Verbalis
exaly